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i g h l i g h t s
Opioid-induced bowel dysfunction and constipation (OIC) are underdiagnosed and undertreated.
Pain management and quality of life in chronic pain patients is reduced by OIC.
Conventional laxatives have limited effects on OIC and may cause adverse effects.
Peripherally-acting opioid antagonists that do not enter the brain are effective against OIC without major adverse effects.
An evidence-based practice guideline for OIC based on the GRADE-method is proposed.
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a b s t r a c t
Background and aims: Opioid-induced bowel dysfunction (OIBD) is an increasing problem due to the
common use of opioids for pain worldwide. It manifests with different symptoms, such as dry mouth,
gastro-oesophageal reﬂux, vomiting, bloating, abdominal pain, anorexia, hard stools, constipation and
incomplete evacuation. Opioid-induced constipation (OIC) is one of itsmany symptoms and probably the
most prevalent. The current review describes the pathophysiology, clinical implications and treatment
of OIBD.
Methods: The Nordic Working Group was formed to provide input for Scandinavian specialists in mul-
tiple, relevant areas. Seven main topics with associated statements were deﬁned. The working plan
provided a structured format for systematic reviews and included instructions on how to evaluate the
level of evidence according to the GRADE guidelines. The quality of evidence supporting the different
statements was rated as high, moderate or low. At a second meeting, the group discussed and voted on
each section with recommendations (weak and strong) for the statements.
Results: The literature review supported the fact that opioid receptors are expressed throughout the
gastrointestinal tract. When blocked by exogenous opioids, there are changes in motility, secretion and
absorption of ﬂuids, and sphincter function that are reﬂected in clinical symptoms. The group supported
a recent consensus statement for OIC, which takes into account the change in bowel habits for at least
one week rather than focusing on the frequency of bowel movements. Many patients with pain receive
opioid therapy and concomitant constipation is associated with increased morbidity and utilization of
healthcare resources. Opioid treatment for acute postoperative pain will prolong the postoperative ileus
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and should also be considered in this context. There are no available tools to assess OIBD, but many
rating scales have been developed to assess constipation, and a few speciﬁcally address OIC. A clinical
treatment strategy for OIBD/OIC was proposed and presented in a ﬂowchart. First-line treatment of OIC
is conventional laxatives, lifestyle changes, tapering the opioid dosage and alternative analgesics. Whilst
opioid rotation may also improve symptoms, these remain unalleviated in a substantial proportion of
patients. Should conventional treatment fail,mechanism-based treatmentwith opioid antagonists should
be considered, and they show advantages over laxatives. It should not be overlooked that many reasons
for constipation other than OIBD exist, which should be taken into consideration in the individual patient.
Conclusion and implications: It is the belief of this Nordic Working Group that increased awareness of
adverse effects andOIBD, particularly OIC, will lead to better pain treatment in patients on opioid therapy.
Subsequently, optimised therapywill improve quality of life and, froma socio-economic perspective,may
also reduce costs associated with hospitalisation, sick leave and early retirement in these patients.
© 2016 The Authors. Published by Elsevier B.V. on behalf of Scandinavian Association for the Study of
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. Introduction and methods
This review summarizes the consensus recommendations of
he multidisciplinary Nordic Working Group on the clinical care
f patients with opioid-induced bowel dysfunction (OIBD) and
articularly opioid-induced constipation (OIC). Opioid-induced
owel dysfunction is a pharmacologically induced condition,which
anifests with different symptoms, such as dry mouth, gastro-
The aim of the current work was to evaluate the avail-
able literature on the deﬁnition, diagnosis and management
of OIBD/OIC using the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE)method (http://www.
gradeworkinggroup.org/publications/JCE series.htm) to aid Nordic
healthcare personnel to expand their understanding of OIBD/OIC.
The group was formed to provide multidisciplinary expert input
for the report and included Scandinavian specialists in differ-esophageal reﬂux, vomiting, bloating, abdominal pain, anorexia,
ard stools, constipation and incomplete evacuation [1,2]. Opioid-
nduced constipation is one of the many symptoms of OIBD and
robably the most prevalent and bothersome symptom. Since opi-
ids affect the enteric nervous system throughout the gut, OIBD is
he most appropriate term, although for practical and traditional
easons most studies have focused on OIC.ent relevant areas. Six members of the Nordic Working Group
(AMD, PM, MS, HB, UK, JGH) formed the Steering Committee and,
after an opening meeting, wrote the initial manuscript over a six-
month period and proposed seven main topics with associated
statements. The working plan provided a structured format for
systematic reviews, and included instructions on how to evalu-
ate the level of evidence and clinical implications according to
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he GRADE guidelines, as adapted for “UpToDate” (http://www.
ptodate.com/home/grading-tutorial). Evidence, where available,
as ranked according to the GRADE method; in the absence or
imited availability of literature, theNordicWorkingGroupdecided
f a recommendation would be included in the consensus report.
he quality of evidence supporting the different statements was
raded as (i) “high” if there was very low probability of further
esearch completely changing thepresented conclusions, (ii) “mod-
rate” if further research may completely change the conclusions,
iii) “low” if further research is likely to change the presented con-
lusions completely. The term “very low” (iv) could be used if
ew researchwillmost probably change the presented conclusions
ompletely; however, the term was not used in the present work.
During a second meeting, after receiving instructions on how to
rade both the level of evidence and strength of the recommen-
ations, ﬁve members of the Steering Committee (MS excused)
iscussed and voted on each section; recommendations could be
weak”, “strong” or “not applicable”. The ﬁnalmanuscript was then
eviewed critically and commented upon by specialists in pharma-
ology (LLC), nursing (MF) and general practice (LA) to ensure a
ultidisciplinary approach and general relevance and applicability
f the conclusions.
Based on these evaluations, theNordicWorkingGroup created a
linical treatment strategy for OIBD/OIC in the advent of newmedi-
ations speciﬁcally designed to treat thedebilitating adverse effects
f opioid treatment.
. Mechanisms of opioid-induced bowel dysfunction
Delta- (-), kappa- (-) and mu- (-) opioid receptors have
een identiﬁed in the gastrointestinal tract [3]. Whilst they are
redominantly present in the enteric nervous system, their rela-
ive distribution varies with region and histological layers of the
ut and, most importantly, between species [4,5]. In humans, -
eceptors are considered to be of greatest importance and have
een identiﬁed in neuronal cells of submucosal and myenteric
eurones and on mononuclear cells in lamina propria [5]. Whilst
ndogenous ligands inﬂuence normal regulation of gastrointestinal
unction, opioid receptors are also activated by exogenous opi-
ids [5–7]. All opioid receptors belong to the G-protein-coupled
eceptor family. Opioid-induced intracellular signalling is com-
lex and involves direct activation of K+-channels (membrane
yperpolarization) and inhibitionofCa2+-channels (decreasedneu-
otransmitter release); it may also involve Na+-channels [8]. The
ain effect, however, is probably decreased formation of cyclic
denosine monophosphate [9], which subsequently activates sev-
ral target molecules and leads to decreased neuronal excitability
ith an overall inhibitory effect on the cells.
Opioid receptor activation in the gut has three main effects:
i) a change in gut motility, (ii) decreased gut secretion, and (iii)
ncreased sphincter tone. Gutmotility is controlled from themyen-
ericplexusvianeurotransmitters releasedonto the smoothmuscle
ells [1,10]. Since opioid administration inhibits release of these
eurotransmitters, it directly causes abnormal coordination of gut
otility as reﬂected by increased tone and decreased propulsive
ctivity. Results from in vivo human studies have conﬁrmed that
pioid administration causes oesophageal and gallbladder dys-
otility, increased stomach tone [10–13], and delays in gastric
mptying, oral-coecal transit and colonic transit [14–16].
Intestinal ﬂuid secretion is essential for an ideal intestinal envi-
onment. In the gut, the submucosal plexus (inﬂuenced by opioid
eceptors) controls local secretory and absorptive activity of the
pithelial cells [17,18]. Opioids inactivate chloride channels and
ecrease chloride transport from the enterocyte into the gut lumen
nd less water follows due to lower osmotic gradient [7,19]. Thisnal of Pain 11 (2016) 111–122 113
results in decreased gut secretion and absorption of water together
with less gastric and pancreatico-biliary secretion [4,20,21]. Slow-
ing of gut motility also allows more time for water absorption.
The resultant decrease in faecal volume negatively affects motility
since intrinsic reﬂexes that cause propulsive contractions depend
on mechanoreceptor activation [4].
The knowledge on the opioid effect on human sphincters is
limited, since only few studies have been carried out.Moreover, the
inﬂuence on, for example, the lower oesophageal sphincter is still
controversial. Nonetheless, results from most studies have shown
opioid treatment to cause increased resting pressure but abnormal
coordination that leads to symptoms, such as reﬂux and sphincter
of Oddi spasms [22–24]. Opioid-induced dysfunction of anorectal
function is especially relevant because contraction leads to exces-
sive straining and incomplete evacuation. The importance of anal
sphincter dysfunction has only been evaluated sparsely [16], but
results from preclinical studies indicate that opioids inhibit the
detection of stools and internal anal sphincter relaxation [25,26].
2.1. Statements according to GRADE
• Opioid receptors are expressed throughout the gastrointestinal
tract and are involved in an array of cellular functions (high qual-
ity, strong recommendation)
• Opioids cause motility changes that instigate slowing of nor-
mal motility, segmentation, increased tone and dis-coordinated
motility (moderate quality, strong recommendation)
• Opioids decrease gut ﬂuid secretion, causing dry faeces and less
propulsive motility (low quality, strong recommendation)
• Opioids increase sphincter tone, which may lead to symptoms,
such as sphincter of Oddi spasms and defecation difﬁculties
(moderate quality, strong recommendation).
3. Deﬁnition and diagnosis of opioid-induced constipation
No generally accepted deﬁnition of OIC exists; methods used
to deﬁne OIC differ across disciplines and studies [27]. Neverthe-
less, the majority of deﬁnitions consider the history of current or
recent opioid treatment combined with some of the symptoms
used to deﬁne functional constipation according to the Rome III
criteria [28], particularly infrequent, hard or lumpy stools, straining
and incomplete evacuation [29]. Yet such deﬁnitions may over-
look many patients suffering from constipation; their deﬁnitions
of constipation after initiating opioid treatment are often subjec-
tive and based on bowel habits before treatment initiation [30].
Moreover, other conditions that cause or exacerbate constipation,
such as metabolic and neurological conditions, mechanical colonic
obstruction, non-opioid drugs and any underlying rectal evacua-
tion disorder (more common than previously thought), should be
excluded with reasonable certainty before diagnosing OIC [31].
A recently published consensus statement and proposed OIC
deﬁnition by a multidisciplinary working group has taken into
account the change in bowel habits from baseline recorded for at
least one week as opposed to a speciﬁc number of bowel move-
ments per week [32]. The group proposed that OIC is deﬁned as a
change frombaselinebowelhabitsuponopioid treatment initiation
characterized by any of the following symptoms:
• Reduced bowel movement frequency
• Developmentorworseningof straining topassbowelmovements
• A sense of incomplete rectal evacuation
• Harder stool consistency.
The need for future psychometric validation of this deﬁnition
and the possibility of restricting it by requiring that two or more of
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he aforementioned symptoms are present before OIC is diagnosed
ere acknowledged. This deﬁnition was supported by a systematic
eview in 2015 byGaertner et al. [33]who analysed 47 publications
elating to the deﬁnition of OIC. They concluded that a deﬁnition of
IC should include (a) objective measures such as stool frequency,
b) patient reported outcome measures, and (c) a change in these
arameters since initiation of opioid therapy. The RomeCommittee
s also working on a deﬁnition of OIC for the forthcoming Rome IV
riteria for functional gastrointestinal disorders.
Notably, some patients suffer from abdominal pain that worsen
espite escalating doses of opioids [34]. This condition is labelled
narcotic bowel syndrome” and has many similarities with the
pioid-inducedhyperalgesiadescribed in somatic tissues; it is char-
cterized by allodynia and/or hyperalgesia that, paradoxically, is
aused by opioid use and fails to improve despite increased dosing.
he mechanism is centrally mediated and should be distinguished
rom OIBD where the pathophysiology is peripheral. For a review,
lease see Kurlander and Drossman [35].
.1. Statement according to GRADE
Opioid-induced constipation can be deﬁned as a change from
baseline bowel habits upon opioid treatment initiation, char-
acterized by any of the following symptoms: reduced bowel
movement frequency; development or worsening of straining to
pass stool; a sense of incomplete rectal evacuation; and/or harder
stool consistency (low quality, strong recommendation).
. Epidemiology and cost of opioid-induced constipation
Opioid-inducedconstipation is anunderdiagnosed, yet common
nd debilitating adverse effect of opioid treatment. Many patients
ith acute and chronic, moderate-to-severe pain receive opioid
reatment [32]. In the US, more than 240 million opioid prescrip-
ions are dispensed per year, themajority for non-cancer pain, such
s back pain and other musculoskeletal causes [36]. In placebo tri-
ls, constipation occurs in 11% of patients, whereas the chronic
onstipation frequency ranges from 33 to 94% in non-cancer and
ancer opioid-treated patients [37–42] (Table 1).
The frequency of OIC varies depending on the number and types
f opioids used [38,39] and acute OIC also occurs when opioids
re used to treat acute pain [11]. In the Patient Reports of Opioid-
elated Bothersome Effects (PROBE) survey of 322 patients with
hronic pain in the US and EU, 33% stated that they had missed
oses, decreased the dose of or stopped using opioid medication in
rder to relieve bowel-related side effects; 92% of patients subse-
uently experienced increased pain, 86% of whom reported that it
educed their Quality of Life (QoL) and daily activities [37,39].
In the non-interventional, Swedish UPPSIKT study that included
atients treated with all types and administration forms of strong
pioids during sixmonths, 60–70% of the 197OIC patients reported
ome degree of bothersome constipation each month. Moreover,
pproximately 12% of patient-months were categorized as months
ith severe problems due to OIC, 25% asmoderate, 26% asmild and
7% asmonthswith no constipation [43]. Clearly, OIC is uncomfort-
ble, affects patient QoL and mortality and can prevent effective
linical management of pain.
able 1
revalence of opioid-induced constipation (OIC) in chronic opioid users.
OIC
Single opioid [37] 67%
Patients± cancer [36,42] 33–70%
Non-cancer patients [39–41] 41–57%
Patients with cancer [40] 94%nal of Pain 11 (2016) 111–122
Constipation may lead to colonic distension, ileus and perfora-
tion [44] and is associated with increased morbidity and increased
utilization of healthcare resources [45,46]. Indeed, the economic
burden of constipation is substantial in terms of both direct and
indirect costs [47–49]. The direct costs include physician visits,
hospitalisation, procedures and medications. Indirect costs include
self-medication, lost earnings, restricted activity and costs of care-
givers [48]. Hence, opioid use is expensive to society and costs
vary with OIC severity [43]. Patients with severe constipation incur
the highest total costs, i.e., 1525 EUR per patient-month, whereas
patientswithmild,moderate and no problems cost 1196 EUR, 1088
EUR, and 1034 EUR, respectively [43]. The indirect cost associated
with sick leave is the largest cost item across all disease severity
groups [43].
4.1. Statements according to GRADE
• Many patients with acute and chronic, moderate-to-severe pain
receive opioid treatment (moderate quality, strong recommen-
dation)
• The majority of opioids are prescribed for non-cancer pain (high
quality, strong recommendation)
• Constipationmay lead to colonic distension, ileus andperforation
(moderate quality, strong recommendation)
• Constipation is associated with increased morbidity and uti-
lization of healthcare resources (moderate quality, strong
recommendation)
• The economic burden (direct and indirect costs) of constipation
is high (moderate quality, strong recommendation).
5. Assessment tools for opioid-induced bowel dysfunction
The ﬁrst step in diagnosing constipation is to clarify the patient
complaints. Opioid-induced bowel dysfunction has a plethora of
symptoms, many of which resemble other conditions. A set of
deﬁnitive diagnostic criteria, therefore, would clearly aid clinicians
in understanding the different mechanisms involved and initiating
a treatment strategy to solve this problem.
Many rating scales for assessing constipation, each of which
addresses a speciﬁc need, have been developed over the past 20
years. The high number of constipation scales highlights increas-
ing awareness of this disorder, yet also suggests that individual
scales are not sensitive enough to assess constipation in all patient
types. A systematic search for assessment scales identiﬁed 16 stud-
ies focused on a selection of diverse symptoms of constipation.
The scales were evaluated in different patient groups [50]. Table 2
shows the most common rating scales, all of which potentially can
be used for OIC.
Whilst some of these scales are easy to use in daily clinical
practice, particularlywhen the cause of constipation is known, oth-
ers are time consuming and adapted primarily for research. Four
different assessment scales have been used for OIC [51,52,55,58]
(Table 2); probably the most straightforward is the Bowel Function
Index (BFI). The three numerical scales of the BFI provide a single,
easy, scoring method (ease of defecation+ feeling of incomplete
bowel evacuation+patient’s personal judgment of constipation).
Inclusion of these items in the BFI is supported by psychomet-
ric tests that demonstrate validity, reliability and responsiveness
[50,58,62,63]. Recently, Argoff et al. [64] reviewed 5 validated
assessments for constipation and concluded that BPI is the most
practical and easy-to-use tool in clinical assessment of OIC. Per-
mission from Mundipharma may be needed, however, to use the
scale in clinical trials. Outcome measures were also evaluated in
the systematic review from Gaertner et al. [33] as mentioned pre-
viously. They concluded that single surrogate measures such as
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Table 2
An overview of the most common constipation assessment tools.
Acronym Name Studies No. of items Patient groups
CSS Constipation Scoring System (Cleveland Clinic Score) Agachan 1996 [51] 8 Chronic constipation and OIBD
CAS Constipation Assessment Scale McMillan 1989 [52] 8 OIBD
KESS The Knowles–Eccersley–Scott symptom questionnaire Knowles 2000 [53] 11 Chronic constipation
SBFQ Subjective Bowel function Questionnaire Griffenberg 1997 [54] 20 Chronic constipation
PAC-SYM Patient Assessment of Constipation Symptoms Frank 2001 [55] 36 OIBD
VSAQ Visual Scale Analogue Questionnaire Pamuk 2003 [56] 4 Chronic constipation
GQ Garrigues Questionnaire Garrigues 2004 [57] 21 Chronic constipation
BFI Bowel Function Index Rentz 2009 [58] 3 OIBD
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tool consistency should be avoided and replaced with a com-
ined measure including (a) objective assessments such as the
ristol Stool Form Scale, (b) integrate patient reported outcome
easures such as BFI and (c) assess the patients’ burden of
IC.
Notably, there is no consensus as to which assessment tools
hould be used for the whole spectrum of OIBD, either in clini-
al practice or in research studies. Whilst standardized assessment
cales are used in some studies [63–66], other intervention studies
eport primarily on spontaneous bowel movements and laxative
se [67,68]. Questionnaires, such as the Gastrointestinal Symp-
om Rating Scale, are well validated, available in many languages
nd assess most relevant gastrointestinal symptoms [70]. Sensi-
ivity to opioid-induced adverse effects, however, requires further
nvestigation; such a questionnaire would require supplementary
uestions to increase its speciﬁcity for OIBD.
Physical examination is always important, for example, check-
ng for palpable masses and anal sphincter tone in order to
xclude faecal impaction. Other diagnostic investigations, such
s colonoscopy, abdominal radiographs [71], colonic transit time
tudies [53] and anorectal physiology measurement may also be
ecessary to unravel the reasons behind constipation yet these
ools are more expensive and not always easily accessible. An opti-
al diagnosis of OIBD essentially requires patient diaries, including
nformation on bowel movements, stool consistency, pain, use of
escue laxatives and opioid medication.
.1. Statements according to GRADE
No consensus in the choice of assessment tools for OIBD or OIC
exists (moderate quality, strong recommendation)
The Bowel Function Index (BFI) is a valid, reliable and responsive
tool to assess OIC (moderate quality, strong recommendation).
. Opioid-induced constipation in postoperative settings
Postoperative pain will, like all acute pain conditions, inhibit
astrointestinal motility partly due to increased sympathetic
xcitation of the intestines. This “normal” postoperative gastroin-
estinal ileus resolves spontaneously once the pain and stress
fter the surgical trauma dissipate. Epidural analgesia with weak
oncentrations of a local anaesthetic drug infused into the tho-
acic and thoraco-lumbar epidural space dramatically reduces the
ime to ﬁrst bowel movement after abdominal surgery [72–74].
his effect is partially antagonised by co-administration of mor-
hine, but maintained if either a low concentration (2g/ml) or
ose (20g/h) of fentanyl is co-administered with the local anaes-
hetic and adrenaline [75,76]. It is also well documented that
pioid treatment for postoperative pain will prolong postopera-
ive ileus [77] especially after abdominal surgery with intestinal
esection/anastomosis [78].an 2006 [59],
an 2006 [60]
Irritable bowel syndrome, functional
constipation
ha 2004 [61] 98 Bowel disorders
Opioid-induced, postoperative constipation can be reduced by
co-administering a peripherally-acting mu-opioid receptor antag-
onist (PAMORA) [1]. For example, the PAMORA alvimopan is
reported to signiﬁcantly reduce the time to ﬁrst bowel move-
ment after bowel surgery and is approved only for the prevention
or shortening of the duration of postoperative ileus after bowel
resection [78]. However, results from long-term safety studies have
indicated that alvimopan may increase the risk of adverse cardio-
vascular eventsandso far alvimopan is available solely in theUSand
restricted for hospital use only. Interestingly, a six- to twelve-fold
higher dose of alvimopan (12mg/day) is required for the preven-
tion/reversal of OIC after bowel surgery in opioid-naïve patients
compared to that needed to reverse OIC in chronic pain patients on
long-term opioid treatment (1–2mg/day) [11,79].
6.1. Statements according to GRADE
• Opioid analgesic treatment for acute postoperative pain will
prolong the postoperative ileus (moderate quality, strong recom-
mendation)
• Opioid-induced constipation and bowel dysfunction, including
post-operative ileus, can be reduced signiﬁcantly by PAMORAs
(moderate quality, weak recommendation).
7. Differential diagnosis of opioid induced bowel
dysfunction
Other gastrointestinal disorders may present with the same
symptoms as OIBD. Patients frequently experiencing chronic
constipation or irritable bowel syndrome (IBS) with constipa-
tion for long periods of time are particularly susceptible to
increased complaints upon initiation of opioid treatment. Gas-
troduodenal ulcerations induced by, for example, non-steroidal
anti-inﬂammatory drugs (NSAIDs) with or without complications
may underlie the nausea, pain or even vomiting in the case of
pyloric stenosis [80]. Gastro-oesophageal reﬂux disease is also
aggravated by NSAIDs, and predisposed patients may experience
worsening of symptomswith increasing time spent in a recumbent
position; it may also contribute to upper abdominal symptoms. In
such cases, upper gastrointestinal endoscopy or even 4–8 weeks’
treatment with a proton pump inhibitor is often indicated [81].
Intestinal obstruction due to tumours (primary or secondary) can
mimic symptoms of severe constipation and should also be ruled
out as a cause of new abdominal complaints, particularly in cases
with a history of malignant disorders. Moreover, nausea may be
caused by intracranial pathology, including central nervous system
(CNS) tumours. Finally, clinicians should also be aware of the “nar-
cotic bowel syndrome” which is an equivalent of opioid induced
hyperalgesia in somatic diseases [34]. The syndrome is charac-
terized by chronic or intermittent abdominal pain, which often
increases in severity despite continued or escalating dosages of
opioids, and treatment is opioid withdrawal.
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.1. Statements according to GRADE
Polypharmacy with medications, such as NSAIDs, may cause
abdominal complaints that can be mistaken for OIBD (medium
quality, strong recommendation)
Abdominal disorders, including gastroduodenal ulcerations and
the narcotic bowel syndrome, may mimic OIBD and patients
should be investigated when in doubt (high quality, strong rec-
ommendation)
Abdominal malignant disease may cause intestinal obstruction,
which must be ruled out (medium quality, strong recommenda-
tion).
. Non-pharmacological and pharmacological treatment of
pioid-induced bowel dysfunction
.1. Fibres, diet and exercise
The basic advice of clinicians to patients complaining of consti-
ation, such as having a high ﬁbre dietary content and ample daily
ntake of ﬂuid volumes, has been difﬁcult to prove efﬁcacious [82]
nd has not been speciﬁcally evaluated in OIBD. The type of dietary
bre is likely to be important; ispaghula (psyllium) is commonly
ecommended because it is associated with fewer complaints of
ntestinal gas, as are probiotics [83]. Although physical exercise
ncreases gastrointestinal motility in healthy subjects [84,85] and
ts usefulness in chronic constipation associated with IBS has not
eenwell documented [86], and speciﬁc information on its efﬁcacy
n OIBD is lacking. Nevertheless, mild exercise should at least be
ecommended due to its positive inﬂuence on appetite and social
ctivities, althoughmany patients are treatedwith opioids because
f back pain or other musculoskeletal disorders, which limit the
ossibility of recommending increased physical exercise.
.1.1. Statements according to GRADE
Soluble ﬁbre, such as ispaghula, is effective in relieving constipa-
tion, including OIC (low quality, weak recommendation)
Physical exercise is likely to be beneﬁcial in reducing complaints
of OIC (medium quality, weak recommendation).
.2. Conventional laxatives
Treatment with conventional laxatives is commonly recom-
ended in all opioid-treated patients [87]. Laxatives can be divided
nto different subgroups, including osmotic agents (magnesium,
actulose, polyethylene glycol), stimulant laxatives (bisacodyl,
enna), and bulking agents (methylcellulose, psyllium). Combined
reatment with osmotic laxatives and stimulant agents are often
ecommended despite anecdotal evidence for laxatives in this set-
ing and no evidence when preferring one laxative agent over the
ther. Usually, oral laxative treatment is initiated, and enemas are
sed in many patients especially when constipation affects the
ost anal segments of colon.
The efﬁcacy of laxatives in the treatment of functional constipa-
ion is still debatable [88,89]. As pointed out by Brenner and Chey
n a recent review, most conventional laxatives are insufﬁcient for
reatment of OIBD [90], possibly because the key symptoms related
o opioid receptor blockade in the gastrointestinal tract are not tar-
eted by laxatives, which primarily affect the colon [1,91]. As a
onsequence of the current lack of randomized, controlled, double-
linded trials investigating the efﬁcacy of conventional laxatives in
IC patients, no evidence exists to suggestwhich laxatives are ben-
ﬁcial. Results from a study in OIC patients, however, showed that
hen the choice of rescue laxative was left to the patients, approx-
mately 80–90% preferred stimulant laxatives [92]. Furthermore,nal of Pain 11 (2016) 111–122
it has been shown that prophylactic administration of laxatives in
opioid-naïve patients generally was effective in preventing OIC. In
this Japanese studymagnesiumoxide and sennaweremostly used;
however, no apparent difference in efﬁcacy between the laxatives
was demonstrated [93].
Moreover, laxative treatment per se may cause side effects, such
as bloating, abdominal distension, rumbling, ﬂatulence and gastro-
oesophageal reﬂux. Together with the possible lack of efﬁcacy, this
may explain why approximately one third of patients omit, reduce
orevendiscontinue their opioid treatment to relieveadverseeffects
insteadof taking laxatives [36]. Sugar andsugar alcoholmetabolism
by intestinal microbiota produces short chain carbonic acids and
gas, which may lead to or worsen the abdominal distension in
OIBD [94]. Many of the bothersome symptoms associated with
OIC, therefore, may not be improved by treatment with laxatives.
Indeed, large-scale studies report that most (81%) patients treated
chronicallywith opioids suffer fromOIC despite using laxatives [2].
However, sincemanypatients do experience a sufﬁcient effectwith
conventional laxatives,most ofwhich are relatively cheap, conven-
tional laxatives are still recommended as ﬁrst-line treatment inOIC
patients (see Fig. 1, Section 9).
8.2.1. Statements according to GRADE
• Laxatives are recommendedasﬁrst-line treatment inOICpatients
(low quality, strong recommendation)
• Recommendations often suggest combined treatment with stool
softeners and stimulant agents (low quality, weak recommenda-
tion)
• Laxative treatment in OIBD may cause side effects per se (high
quality, strong recommendation).
8.3. Opioid rotation and alternative opioids
An individual’s responsiveness and sensitivity to opioids
involves interplay between genetic, physiological, and pharma-
cokinetic and -dynamic factors; together these determine both
the analgesic response and tolerance to a particular drug [95].
Opioids may have a direct local effect on opioid receptors in the
gastrointestinal tract, and changing from oral to parenteral or
transdermal administration may partially alleviate symptoms of
OIC/OIBD. Results from two studies have indicated that transder-
mal administration of fentanyl administered is associated with a
signiﬁcantly lower rate of constipation than morphine adminis-
tered orally [96,97], although a Cochrane review of its effects and
side effects stated that constipation was reported inconsistently
[98]. Hence, gut receptors invariably will be affected when opioids
reach the systemic circulation and, from amechanistic perspective,
transdermal treatment may not be better than systemic adminis-
tration.
Gastrointestinal function in OIBD patients may be improved
by rotating one opioid with another, whilst maintaining analge-
sia [99–101]. The balance between cross-tolerance to analgesic
response and adverse effects contribute to the relative success of
any rotation. Opioid rotation is frequently used in clinical practice;
however, few prospective, randomized trials that support opioid
rotation for either efﬁcacy or adverse effects exist.
The “new” opioid tapentadol, used for pain relief, is both a -
opioid agonist and norepinephrine reuptake inhibitor; it exhibits
weaker -receptor activity than pure opioid agonists [102] and
maybeassociatedwitha lower incidenceof constipation thanother
opioids [103,104]. When patients with lower back or osteoarthritis
pain were treated with tapentadol, oxycodone or placebo, tapenta-
dol was shown to cause less bowel function impairment than oxy-
codone, i.e., signiﬁcantly fewer days without a bowel movement,
softer stools, less straining, and improved constipation assessment
scores [105]. The proportions of treatment days with no bowel
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hus continuation to next step. Treatment goals are to establish regular bowel fun
omplications, such as haemorrhoids, rectal prolapse and faecal impaction. As supp
here a score >30 should lead to more intensive treatment.
ovements or with incomplete bowel movements were similar
mong tapentadol- and placebo-treated patients. A recent system-
tic review in which prolonged-release oxycodone/naloxone were
ompared with extended-release tapentadol, however, favoured
he oxycodone/naloxone combination regarding patient-reported
onstipation [106].
Daeninck and colleagues [107] reported on four cancer pain
atients with OIBD who experienced an improvement in con-
tipation and a reduction in laxative dose after opioid rotation
o methadone. Results from another study demonstrated signif-
cant improvement in several morphine-related adverse effects,
ncluding constipation, in 52 cancer patients after rotation to
ethadone [108]. Moreover, a study of 189 consecutive patients
ho underwent methadone initiation/rotation showed improved
onstipation and nausea after the initiation/rotation [104]. These
ndings, however, must be conﬁrmed in prospective studies with
learly deﬁned endpoints and longer follow-up periods.
.3.1. Statements according to GRADE
Tapentadol causes less bowel function impairment than oxy-
codone (moderate quality, strong recommendation)
Transdermal fentanyl is associatedwith a signiﬁcantly lower rate
of constipation than oral morphine (low quality, weak recom-
mendation)
Rotation from different opioids to methadone leads to reduced
laxative doses and an improvement in constipation (low quality,
weak recommendation).
.4. Other treatments relevant for opioid-induced constipation
In patients suffering from OIBD, tapering the opioid to low-
st possible dose or replacing it with other analgesics may be
ptional. Non-opioid analgesics are often insufﬁcient in treating
hronic pain, although guidelines recommend a basic regimen of
aracetamol (acetaminophen) to reduce the required opioid dose
109,110]. Adjuvant analgesics, such as anti-epileptics (e.g., car-
amazepine, gabapentin and pregabalin), are also recommendedcially constipation. The arrows indicate a failure of the ﬁrst recommendation and
and eliminate upper gastrointestinal symptoms, improve quality of life and avoid
r clinical evaluation questionnaires such as the Bowel Function Index may be used,
therapies for chronic pain, although mainly proven efﬁcacious in
speciﬁc conditions like neuropathic pain associated with diabetes
mellitus or post-herpetic nerve injury [111]. In humans, a recent
meta-analysis conﬁrmed that at doses of 1200mg daily or more,
gabapentin was associated with pain reduction in signiﬁcantly
more patients than placebo, but the “number needed to treat” was
as high as 6–8 for neuropathic pain and little documentation exists
for other pain conditions [112]. Recently, morphine requirement
in the 72-hour postoperative phase was investigated in patients
randomized either to gabapentin or placebo, yet no difference in
morphine consumption or in adequacy of pain relief was seen
[113].
Various classes of antidepressants, often at low doses, are also
used to treat neuropathic and other chronic conditions of pain
and may reduce the opioid dose. A Cochrane review of the differ-
ent antidepressant classes was optimistic in its support for using
antidepressants to avoid opioid treatment [114]; in contrast, recent
reviews of single antidepressants have shown little evidence for
this [115,116]. Notably, the balance between adverse effects and
analgesia often lead to other treatment alternatives.
Apart fromchanges in analgesic therapy, new treatment options
are available for chronic idiopathic constipation and IBS with con-
stipation and can potentially be used in special cases in patients
with OIC. For example, lubiprostone speciﬁcally activates the ClC-2
chloride channels on the apical aspect of gastrointestinal epithe-
lial cells to produce a net secretion into the gut lumen [117]. This
softens the stools, stimulates motility and increases the number of
spontaneous bowel movements. Lubiprostone was tested success-
fully in patients with chronic idiopathic constipation [118] and IBS
with constipation [119] and recent randomized, placebo-controlled
trials showed that it effectively relieves OIC and associated signs
and symptoms, whilst being well tolerated in chronic, non-cancer
pain patients [120,121]. Conversely, another smaller study showed
no advantage of lubiprostone compared to the less expensive senna
in postoperative orthopaedic surgery patients [122]. The drug has
been approved for OIC in adults with chronic, non-cancer pain in
the US since 2013, but not in Europe.
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Linaclotide is a potent and selective guanylate cyclase C ago-
ist,which induces secretion into the gut lumen, accelerates transit
nd reduces pain perception [123,124]. In large clinical trials, lina-
lotide improved abdominal and bowel symptoms in patients with
hronic idiopathic constipation [125] and IBS with constipation
126]. Based on its mechanism of action, it is likely to be effective
n OIC; currently a clinical trial programme is underway to assess
his. Linaclotide is approved for chronic idiopathic constipation in
he US and for IBS with constipation in the US and in Europe.
Prucalopride is a highly selective 5-HT4 agonist with strong
astro-prokinetic effects [127,128]. Clinical data support its value
n treating chronic idiopathic constipation, where it is safe and
ncreases the number of bowel movements [129]. One Phase
I trial has compared prucalopride with placebo in non-cancer
ain patients with OIC; although several outcome variables were
mproved in the prucalopride group, some failed to reach statistical
igniﬁcance [130]. Prucalopride is currently approved in Europe
or women with chronic constipation in whom laxative treatment
as failed.
.4.1. Statements according to GRADE
Pregabalin and gabapentin may be effective alternative thera-
pies for relieving neuropathic and other chronic pain conditions
(moderate quality, strong recommendation)
Antidepressants may be useful in treating neuropathic pain
(moderate quality, weak recommendation)
Lubiprostone can be tried for OIC (moderate quality, strong rec-
ommendation)
Prucalopride can be tried for OIC (low quality, weak recommen-
dation)
Linaclotidecanbe tried forOIC (lowquality, no recommendation).
.5. Combination therapies: slow-release tablets with an opioid
gonist and peripherally-restricted opioid antagonist
slow-release oxycodone and naloxone)
Naloxone is the classical opioid antagonist, which,when admin-
steredbyparenteral injection, reverses all effects of opioid agonists
nd precipitates severe pain and withdrawal symptoms in chronic
ain patients on long-term opioid treatment. Orally administered
aloxone is well absorbed from the gastrointestinal tract and is
ubject to an extensive ﬁrst pass metabolism. In a randomized
linical trial (RCT), however, the effect of either 2mg or 4mg of
aloxone administered three times to nine patients with consti-
ation on stable doses of opioids was evaluated [131]. All patients
ho received oral naloxone showed some improvement in bowel
requency, although the analgesic effect was reversed in three
atients. Thus, when given orally in conventional tablets, nalox-
ne might reach the systemic circulation and cause anti-analgesic
nd withdrawal effects. On the other hand, when naloxone is
dministered orally in a prolonged-release formulation, >97% is
etabolised due to the hepatic ﬁrst-pass mechanism, leaving only
iny amounts to reach the systemic circulation and CNS [132,133].
he effect of a combination of prolonged-release (or slow- or
ontrolled-release) oxycodone/naloxone compared to prolonged-
elease oxycodone/placebo has been investigated in four RCTs in a
otal of 974 patients, and inwhich the primary outcomewas the BFI
cores [134–136]. A 2:1 ratio of oxycodone:naloxonewas identiﬁed
y themanufacturer to be themost suitable to ensure alleviation of
onstipation without risk for systemic effects [137]. Doses ranged
etween 40–120mg for oxycodone and 10–60mg for naloxone and
rials lasted 4–12 weeks. Oxycodone/naloxone-treated patients
xperienced improved bowel function compared to those on oxy-
odone/placebo and no serious adverse effects were reported.
Ultra-low doses of naloxone may suppress some of the adverse
ffects ofmorphine, suchasnausea, sedation, and itching [138,139].nal of Pain 11 (2016) 111–122
Hence, improved pain control with intravenous morphine has
been observed even with ultra-low doses of intravenous nalox-
one, which reduces opioid-induced hyperalgesia, allodynia and
tolerance [140–142]. These surprising effects of ultra-low doses
of naloxone may be explained by the hypothesis that -opioid
receptor excitatory G-protein complexes are inhibited whilst the
inhibitory G-protein receptors are left undisturbed [142].
For further information on these aspects of controlled- or slow-
release oxycodone/naloxone, see Breivik and Werner [143] and
Hesselbarth and colleagues [144].
8.5.1. Statements according to GRADE
• Naloxone, taken orally in doses sufﬁcient to treat OIC, may cause
withdrawal symptoms and reverse analgesia (moderate quality,
strong recommendation)
• Slow-release naloxone–oxycodone is more efﬁcacious than oxy-
codone in avoiding OIC (high quality, strong recommendation).
8.6. Peripherally-acting -opioid receptor antagonists
Opioid agonists cause OIBD, including OIC, primarily by bind-
ing to submucosal -opioid receptors in the gastrointestinal tract
(see Section 2). Opioid antagonists that block only these periph-
eral opioid receptors should, therefore, reduce OIBD and OIC with
no reduction in central opioid analgesia. In addition to naloxone
administered in slow-release tablets, the effects of three PAMORAs
(methylnaltrexone, naloxegol and alvimopan) have been evaluated
in RCTs and are available in some countries. Alvimopan is described
in the postoperative section and will be not be dealt with here.
Methylnaltrexone is a quaternary ammonium compound and
thus an extremely polar compound, which does not readily cross
biological membranes, such as the epithelial cells in the gut and
endothelial cells in the blood–brain barrier. Thus, the compound
does not gain access to the CNS and must be administered parente-
rally. The effects ofmethylnaltrexonehavebeen investigated inﬁve
RCTs with different numbers and types of patients suffering from
OIC. Treatment duration, and outcomemeasurements varied in the
single studies (time to defecation, number of patients with drug-
related bowel movements) [92,145–146]. Dosing schedules and
administration routes of methylnaltrexone also differed. Doses of
0.15mg/kg, 0.30mg/kg or a ﬁxed dose of 12mg were administered
daily or every second day, and by intravenous or subcutaneous
injections. Results from all studies showed signiﬁcantly better out-
comes with methylnaltrexone compared with placebo. Secondary
outcomes, such as decreased laxative use, were also reported. Gen-
erally, methylnaltrexone was well tolerated by all patients, but its
high price and parenteral route of administration limits its use.
Naloxegol is a PEGylated derivative of the naloxone molecule;
the PEGylation process prevents it from crossing the blood–brain
barrier due to the increased size of themolecule, as well as reduced
passive and active permeability. Results from twoRCTs have shown
that at a daily dose of 25mg, naloxegol signiﬁcantly increased the
number of days per week with spontaneous and normal bowel
movements (defecations) compared to that seen after adminis-
tration of placebo. Pain intensity and opioid requirements were
unchanged, and no withdrawal symptoms or serious cardiovascu-
lar events were observed [67,69]. Moreover, opioid-induced upper
gastrointestinal dysfunctions improved (i.e., therewas less regurgi-
tationof stomachcontent, heartburnandnausea). It is an advantage
that naloxegol can be used as an add-on to existing pain therapy,
as many pain patients are on a stable and satisfactory analgesic
regime, but suffer from OIBD symptoms [147]. Tack et al. [148]
reported the outcome of two Phase 3 trials conﬁrming the high
efﬁcacy of naloxegol in relieving OIC in patients with laxative-
inadequate response. Naloxegol has been approved by the FDA
in the US and the European Medicines Agency for the treatment
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f laxative-resistant OIC, which includes cancer and non-cancer
atients in Europe.
Three other PAMORAs are in development for the treatment of
IBD: bevenopran, TD-1211 and naldemedine [143].
.6.1. Statements according to GRADE
Methylnaltrexone blocks peripheral opioid receptors and can be
used to reduce OIC (moderate quality, weak recommendation)
Naloxegol blocks peripheral opioid receptors and can be used to
reduce OIC (moderate quality, strong recommendation).
. Conclusions and treatment practice advisory
ecommendations
Opioid-induced bowel dysfunction is an increasing problemdue
o the common use of opioids worldwide. In most countries, con-
urrent use of laxatives with opioids is recommended. Despite
he use of conventional laxatives, however, a substantial portion
f patients still suffers from OIBD, which causes a signiﬁcant
ecrease in QoL [149]. Opioid antagonists with mechanism-based
ocal effects on the gut are, therefore, a well-validated treatment
ption. Awareness of the problem is mandatory for the treating
hysician, and it is important to stress that constipation is only part
f the plethora of OIBD symptoms, which can also be dominated by
ther symptoms, such as reﬂux and gas.
Fig. 1 summarizes a recommendation for OIBD and OIC treat-
ent based on the current evidence outlined in this article. With
egards to conventional laxatives, local traditions often guide treat-
ent choice. Magnesium sulphate, bisacodyl, sodium picosulfate
ndmacrogol are themost frequently used laxatives in Scandinavia
nd recommended as ﬁrst-line medication. Lifestyle changes and
lternative analgesics should always be considered. Tapering the
pioid dosage, opioid rotation and dual action opioids like tapen-
adol may also improve OIBD. Should conventional treatment fail
o alleviate symptoms, mechanism-based treatment with opioid
ntagonists should be considered, which shows advantages over
onventional laxative use. As support for the clinical evaluation
rgoff et al. [64] recently recommended that after evaluation of
rst-line interventions, a BFI score of >30 points should lead to pre-
cription of PAMORAs. These treat OIC effectively and are also likely
o treat other symptoms associated with opioid use, although this
ust still be demonstrated in experimental and clinical studies.
n difﬁcult cases, particularly in hospitalised patients, methylnal-
rexone may be used as an initial “OIC test therapy” due to its
arenteral administration and strong effect that may unmask the
ature of the symptoms. Newer drugs, such as prucalopride, lina-
lotide or lubiprostone may also be tried in speciﬁc cases. It should
ot be overlooked that there are many other reasons for constipa-
ion than OIBD, which should also be taken into consideration in
he diagnosis of an individual patient.
It is the belief of this Nordic Working Group that increased
wareness of adverse effects associatedwithopioid therapy, partic-
larly OIC and OIBD, will lead to better pain treatment in patients.
ubsequently, optimised treatment will improve QoL and, from a
ocio-economic perspective, may also reduce costs associated with
ospitalisation, sick leave and early retirement in patients suffering
rom pain.
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